Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome
Top Cited Papers
- 22 February 2011
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 123 (7), 798-813
- https://doi.org/10.1161/circulationaha.109.913376
Abstract
No abstract availableThis publication has 166 references indexed in Scilit:
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Clinical overview of promising nonthienopyridine antiplatelet agentsAmerican Heart Journal, 2008
- Pharmacology of emerging novel platelet inhibitorsAmerican Heart Journal, 2008
- Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary interventionAmerican Heart Journal, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Peroxisome proliferator-activated receptor-γ agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery diseaseAmerican Heart Journal, 2004
- Insulin-induced expression of prostacyclin receptors on platelets is mediated through ADP-ribosylation of Giα proteinLife Sciences, 1998
- Thromboxane Biosynthesis and Platelet Function in Type II Diabetes MellitusThe New England Journal of Medicine, 1990
- Aspirin, Heparin, or Both to Treat Acute Unstable AnginaThe New England Journal of Medicine, 1988
- Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable AnginaThe New England Journal of Medicine, 1983